Pharma in Focus - knowledge in power
8 - 14 Mar 2010
 
Analysis: HTA changes, more bureaucracy or faster to market?
By July this year the pharmaceutical industry may be facing a new layer of bureaucracy in making market approval reimbursement submissions but there is also hope those submissions will move faster
R&D trend means a challenging trials environment
This week the trend for major pharma companies to re-examine their commitment to R&D came into sharp focus again as AstraZeneca announced where it would implement R&D cuts revealed in general terms some weeks before
Search News Archive

Search terms:
Search:
Search in:
Headline only Article only

Date range:
(dd/mm/yyyy)

to
Ordered by:
Display only the last issue
Issue Date:
Display per page:
 

 

 
Instant Update: Thurs 11 March
..full report
Vioxx claims in hundreds of millions
..full report
Generic fines well below MA levels
..full report
PBAC's last fee-free meeting
..full report
Amgen, Hospira in patent wrangle
..full report
Backlog distorts PBS statistics
..full report
Combos stopped osteo drug decline
..full report
Reckitt fights back on Nurofen Plus
..full report
IT bungle delays PI, CMI capture
..full report

© 2007 Lush Media | Privacy Statement | Subscribe to Pharma in Focus